Concepts for design of an energy management system incorporating dispersed storage and generation

New forms of generation based on renewable resources must be managed as part of existing power systems in order to be utilized with maximum effectiveness. Many of these generators are by their very nature dispersed or small, so that they will be connected to the distribution part of the power system. This situation poses new questions of control and protection, and the intermittent nature of some of the energy sources poses problems of scheduling and dispatch. Under the assumption that the general objectives of energy management will remain unchanged, the impact of dispersed storage and generation on some of the specific functions of power system control and its hardware are discussed

Power system applications of fiber optics

Power system applications of optical systems, primarily using fiber optics, are reviewed. The first section reviews fibers as components of communication systems. The second section deals with fiber sensors for power systems, reviewing the many ways light sources and fibers can be combined to make measurements. Methods of measuring electric field gradient are discussed. Optical data processing is the subject of the third section, which begins by reviewing some widely different examples and concludes by outlining some potential applications in power systems: fault location in transformers, optical switching for light fired thyristors and fault detection based on the inherent symmetry of most power apparatus. The fourth and final section is concerned with using optical fibers to transmit power to electric equipment in a high voltage situation, potentially replacing expensive high voltage low power transformers. JPL has designed small photodiodes specifically for this purpose, and fabricated and tested several samples. This work is described

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study

Objectives. To assess long-term efficacy, safety and tolerability of secukinumab up to 104 weeks in patients with active PsA. Methods. Patients with PsA (n = 397) were randomized to s.c. secukinumab 300, 150 or 75 mg or placebo at baseline, weeks 1, 2, 3 and 4 and every 4 weeks thereafter. Placebo-treated patients were re-randomized to receive secukinumab 300 or 150 mg s.c. from week 16 (placebo non-responders) or week 24 (placebo responders). Exploratory endpoints at week 104 included 20, 50 and 70% improvement in ACR criteria (ACR20, 50, 70); 75 and 90% improvement in the Psoriasis Area Severity Index, 28-joint DAS with CRP, presence of dactylitis and enthesitis and other patient-reported outcomes. For binary variables, missing values were imputed; continuous variables were analysed by a mixed-effects model for repeated measures. Results. A total of 86/100 (86%), 76/100 (76%) and 65/99 (66%) patients in the secukinumab 300, 150 and 75 mg groups, respectively, completed 104 weeks. At week 104, ACR20 response rates after multiple imputation in the 300, 150 and 75 mg groups were 69.4, 64.4 and 50.3%, respectively. Sustained clinical improvements were observed through week 104 with secukinumab across other clinically important domains of PsA. Responses were sustained through week 104 regardless of prior anti-TNF-a use. Over the entire treatment period the incidence, type and severity of adverse events were consistent with those reported previously. Conclusion. Secukinumab provided sustained improvements in signs and symptoms and multiple clinical domains in patients of active PsA through 2 years of therapy. Secukinumab was well tolerated, with a safety profile consistent with that reported previously. Trial registration: ClinicalTrials.gov (https://clinicaltrials.gov), NCT0175263

Target value design: using collaboration and a lean approach to reduce construction cost

Target Costing is an effective management technique that has been used in manufacturing for decades to achieve cost predictability during new products development. Adoption of this technique promises benefits for the construction industry as it struggles to raise the number of successful outcomes and certainty of project delivery in terms of cost, quality and time. Target Value Design is a management approach that takes the best features of Target Costing and adapts them to the peculiarities of construction. In this paper the concept of Target Value Design is introduced based on the results of action research carried out on 12 construction projects in the USA. It has been shown that systemic application of Target Value Design leads to significant improvement of project performance – the final cost of projects was on average 15% less than market cost. The construction industry already has approaches that have similarities with elements of the Target Value Design process or uses the same terminology, e.g. Partnering and Target Cost Contracts, Cost planning, etc. Following an exploration of the similarities and differences Target Value Design is positioned as a form of Target Costing for construction that offers a more reliable route to successful projects outcomes

Integrated disease management of leaf spots and crown rust of oat

Non-Peer ReviewedCrown rust and leaf spots can reduce the yield and quality of oats. The objective of this research was to determine the effect of conventional fungicides, Actigard® and oat cultivars that vary in resistance to crown rust on leaf spot and crown rust severity, and oat yield and quality. Two experiments were established at each location in Saskatchewan: Saskatoon and Melfort. Experiment one consisted of three oat varieties: AC Morgan (crown rust susceptible), CDC Dancer (intermediate) and CDC Morrison (resistant) and three fungicide treatments: check (unsprayed), propiconazole and pyraclostrobin. Experiment two consisted of the application of Actigard® at two rates: 8.75 g ai/ha and 26.25 g ai/ha; three crop growth stages: seedling, boot and heading; on two varieties: CDC Dancer and CDC Morrison, with an unsprayed check for each variety. At Saskatoon, crown rust was observed while leaf spot severity was low. At Melfort, no crown rust was observed but leaf spot severity was low to moderate. Fungicide reduced the severity of crown rust and increased yield and quality of oat at Saskatoon for the susceptible variety (AC Morgan) and somewhat for the moderately susceptible variety (CDC Dancer). The crown rust resistant variety (CDC Morrison) did not benefit from fungicide. Leaf spots were reduced by fungicide application at Melfort, but little increase in yield or quality was detected. There was little difference between AC Morgan and CDC Morrison for leaf spot symptoms, but CDC Dancer appeared to suffer slightly more than the other varieties. There was no impact of fungicide on beta-glucan content at either location, although there were differences among varieties, but only at Saskatoon. Actigard® was not observed to have any positive or negative effects on disease severity (crown rust or leaf spots) or any of the factors measured, including nutritional characteristics, at either location, although there were differences among varieties for many of the factors measured

Integrated disease management of leaf spots and crown rust of oat

Non-Peer ReviewedCrown rust and leaf spots can reduce the yield and quality of oats. The objective of this research was to determine the effect of conventional fungicides, Actigard® and oat cultivars that vary in resistance to crown rust on leaf spot and crown rust severity, and oat yield and quality. Two experiments were established at two locations in Saskatchewan: Saskatoon and Melfort. Experiment 1 consisted of three oat varieties: AC Morgan (crown rust susceptible), CDC Dancer (intermediate) and CDC Morrison (resistant) and three fungicide treatments: check (unsprayed), propiconazole and pyraclostrobin. Experiment 2 consisted of the application of Actigard® at two rates: 8.75 g ai/ha and 26.25 g ai/ha; three crop growth stages: seedling, boot and heading; on two varieties: CDC Dancer and CDC Morrison, with an unsprayed check for each variety. At Saskatoon, crown rust was observed while leaf spot severity was low. At Melfort, no crown rust was observed and leaf spot severity was low. Fungicide reduced the severity of crown rust and increased yield and quality of oat at Saskatoon for the susceptible variety (AC Morgan) and somewhat for the moderately susceptible variety (CDC Dancer). The crown rust resistant variety (CDC Morrison) did not benefit from fungicide. Leaf spots were reduced by fungicide application at Melfort, but little increase in yield or quality was detected. There was little difference between AC Morgan and CDC Morrison for leaf spot symptoms, but CDC Dancer appeared to suffer slightly more than the other varieties. There was no impact of fungicide on beta-glucan content at either location, although there were differences among varieties, but only at Saskatoon. Actigard® was not observed to have any positive or negative effects on disease severity (crown rust or leaf spots) or any of the factors measured, including nutritional characteristics, at either location, although there were differences among varieties for many of the factors measured

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Background: Interleukin 17A is a proinflammatory cytokine that is implicated in the pathogenesis of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis. Methods: In this phase 3, double-blind, placebo-controlled study undertaken at 76 centres in Asia, Australia, Canada, Europe, and the USA, adults (aged ≥18 years old) with active psoriatic arthritis were randomly allocated in a 1:1:1:1 ratio with computer-generated blocks to receive subcutaneous placebo or secukinumab 300 mg, 150 mg, or 75 mg once a week from baseline and then every 4 weeks from week 4. Patients and investigators were masked to treatment assignment. The primary endpoint was the proportion of patients achieving at least 20% improvement in the American College of Rheumatology response criteria (ACR20) at week 24. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01752634. Findings: Between April 14, and Nov 25, 2013, 397 patients were randomly assigned to receive secukinumab 300 mg (n=100), 150 mg (n=100), 75 mg (n=99), or placebo (n=98). A significantly higher proportion of patients achieved an ACR20 at week 24 with secukinumab 300 mg (54 [54%] patients; odds ratio versus placebo 6·81, 95% CI 3·42–13·56; p<0·0001), 150 mg (51 [51%] patients; 6·52, 3·25–13·08; p<0·0001), and 75 mg (29 [29%] patients; 2·32, 1·14–4·73; p=0·0399) versus placebo (15 [15%] patients). Up to week 16, the most common adverse events were upper respiratory tract infections (four [4%], eight [8%], ten [10%], and seven [7%] with secukinumab 300 mg, 150 mg, 75 mg, and placebo, respectively) and nasopharyngitis (six [6%], four [4%], six [6%], and eight [8%], respectively). Serious adverse events were reported by five (5%), one (1%), and four (4%) patients in the secukinumab 300 mg, 150 mg, and 75 mg groups, respectively, compared with two (2%) in the placebo group. No deaths were reported. Interpretation: Subcutaneous secukinumab 300 mg and 150 mg improved the signs and symptoms of psoriatic arthritis, suggesting that secukinumab is a potential future treatment option for patients with this disorder